Hepatocellular carcinoma

Nature Reviews Disease Primers, Год журнала: 2021, Номер 7(1)

Опубликована: Янв. 21, 2021

Язык: Английский

---

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

The Lancet, Год журнала: 2017, Номер 389(10088), С. 2492 - 2502

Опубликована: Апрель 21, 2017

Язык: Английский

---

Molecular therapies and precision medicine for hepatocellular carcinoma

Nature Reviews Clinical Oncology, Год журнала: 2018, Номер 15(10), С. 599 - 616

Опубликована: Июль 30, 2018

Язык: Английский

---

Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets

Scientific Reports, Год журнала: 2018, Номер 8(1)

Опубликована: Июнь 11, 2018

Multiple studies suggested using different miRNAs as biomarkers for prognosis of hepatocellular carcinoma (HCC). We aimed to assemble a miRNA expression database from independent datasets enable an validation previously published prognostic HCC. A was established by searching the TCGA (RNA-seq) and GEO (microarray) repositories identify with available clinical data. PubMed search performed uni- multivariate Cox regression analysis validate significance these miRNAs. The Limma R package applied compare between tumor normal tissues. uncovered 214 publications containing 223 identified potential In survival analysis, levels 55 84 were significantly correlated overall in RNA-seq gene chip datasets, respectively. most significant hsa-miR-149, hsa-miR-139, hsa-miR-3677 hsa-miR-146b-3p, hsa-miR-584, hsa-miR-31 microarray dataset. Of studied, altered 102 tumors compared liver summary, we set up integrated validated

Язык: Английский

---

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Journal of Clinical Oncology, Год журнала: 2020, Номер 38(26), С. 2960 - 2970

Опубликована: Июль 27, 2020

PURPOSE The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death receptor-1 (PD-1) signaling inhibitors in hepatocellular carcinoma (HCC). We report results from a phase Ib study plus pembrolizumab (an anti–PD-1 antibody) unresectable HCC (uHCC). PATIENTS AND METHODS In this open-label multicenter study, patients uHCC received (bodyweight ≥ 60 kg, 12 mg; < 8 mg) orally daily and 200 mg intravenously day 1 21-day cycle. included dose-limiting toxicity (DLT) an expansion (first-line patients). Primary objectives were safety/tolerability (DLT phase), objective response rate (ORR) duration (DOR) by modified RECIST (mRECIST) version 1.1 (v1.1) per independent imaging review (IIR; phase). RESULTS A total 104 enrolled. No DLTs reported (n = 6) the DLT phase; 100 (expansion n 2 phase) had no prior systemic therapy Barcelona Clinic Liver Cancer stage B 29) or C disease 71). At data cutoff, 37% remained treatment. Median follow-up was 10.6 months (95% CI, 9.2 11.5 months). Confirmed ORRs IIR 46.0% 36.0% 56.3%) mRECIST 26.6% 46.2%) v1.1. DORs 8.6 6.9 not estimable [NE]) 12.6 NE) progression-free survival 9.3 overall 22 months. Grade 3 treatment-related adverse events occurred 67% (grade 5, 3%) patients. new safety signals identified. CONCLUSION Lenvatinib has promising uHCC. Toxicities manageable, unexpected signals.

Язык: Английский

---

Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis

Gastroenterology, Год журнала: 2016, Номер 152(4), С. 745 - 761

Опубликована: Дек. 30, 2016

Язык: Английский

---

Advances in immunotherapy for hepatocellular carcinoma

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2021, Номер 18(8), С. 525 - 543

Опубликована: Апрель 13, 2021

Hepatocellular carcinoma (HCC) is a prevalent disease with progression that modulated by the immune system. Systemic therapy used in advanced stage and until 2017 consisted only of antiangiogenic tyrosine kinase inhibitors (TKIs). Immunotherapy checkpoint has shown strong anti-tumour activity subset patients combination anti-PDL1 antibody atezolizumab VEGF-neutralizing bevacizumab or will soon become standard care as first-line for HCC, whereas anti-PD1 agents nivolumab pembrolizumab are after TKIs several regions. Other strategies such adoptive T-cell transfer, vaccination virotherapy have not yet demonstrated consistent clinical activity. Major unmet challenges HCC immunotherapy discovery validation predictive biomarkers, advancing treatment to earlier stages disease, applying liver dysfunction more effective combinatorial sequential approaches. Combinations other systemic local treatments perceived most promising opportunities some already under evaluation large-scale trials. This Review provides up-to-date information on best use currently available immunotherapies therapeutic development. Immunotherapeutic interventions might be tools hepatocellular carcinoma. carcinoma, mechanisms response resistance,

Язык: Английский

---

Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives

Cells, Год журнала: 2020, Номер 9(4), С. 875 - 875

Опубликована: Апрель 3, 2020

Liver fibrosis due to viral or metabolic chronic liver diseases is a major challenge of global health. Correlating with disease progression, key factor for outcome and risk hepatocellular carcinoma (HCC). Despite different mechanism primary injury disease-specific cell responses, the progression fibrotic follows shared patterns across main etiologies. Scientific discoveries within last decade have transformed understanding mechanisms fibrosis. Removal elimination causative agent such as control cure infection has shown that reversible. However, reversal often occurs too slowly infrequent avoid life-threatening complications particularly in advanced Thus, there huge unmet medical need anti-fibrotic therapies prevent HCC development. while many candidate agents robust effects experimental animal models, their clinical trials been limited absent. no approved therapy exists In this review we summarize cellular drivers molecular fibrogenesis discuss impact development urgently needed therapies.

Язык: Английский

---

The immunology of hepatocellular carcinoma

Nature Immunology, Год журнала: 2018, Номер 19(3), С. 222 - 232

Опубликована: Янв. 26, 2018

Язык: Английский

---

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

The Lancet Oncology, Год журнала: 2021, Номер 23(1), С. 77 - 90

Опубликована: Дек. 13, 2021

Язык: Английский

---